Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTYPXQF)

• DTT Name: Protein kinase C beta (PRKCB) DTT Info
• Gene Name: PRKCB

Molecule-Related Drug & Molecule List

5 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[1]
RUBOXISTAURIN HYDROCHLORIDE	DMQOCD8	Lymphoma	2A80-2A86	Phase 3	[2]
LY333531	DMGMC8H	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
Sotrastaurin acetate	DME53YS	Renal transplantation	NE84	Phase 2	[4]
MS-553	DM7ER9J	Chronic lymphocytic leukaemia	2A82.0	Phase 1	[5]

4 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Linetastine	DMF8B62	Rhinitis	FA20	Discontinued in Phase 2	[6]
BALANOL	DMDLN9E	N. A.	N. A.	Terminated	[7]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[8]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[9]

23 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(-)-Cercosporamide	DMJ249P	Discovery agent	N.A.	Investigative	[10]
2,3,3-Triphenyl-acrylonitrile	DM7H34U	Discovery agent	N.A.	Investigative	[11]
2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile	DMNGW1A	Discovery agent	N.A.	Investigative	[11]
3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile	DMO51QG	Discovery agent	N.A.	Investigative	[11]
3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile	DMZPYN2	Discovery agent	N.A.	Investigative	[11]
3-(1H-Indol-3-yl)-4-phenylamino-pyrrole-2,5-dione	DMP0RYB	Discovery agent	N.A.	Investigative	[12]
3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile	DME5238	Discovery agent	N.A.	Investigative	[11]
4-cycloheptyliden(4-hydroxyphenyl)methylphenol	DM4LIUC	Discovery agent	N.A.	Investigative	[11]
4-cyclohexyliden(4-hydroxyphenyl)methylphenol	DM8BLK2	Discovery agent	N.A.	Investigative	[11]
4-cyclopentyliden(4-hydroxyphenyl)methylphenol	DM7LN53	Discovery agent	N.A.	Investigative	[11]
4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol	DM8IYG1	Discovery agent	N.A.	Investigative	[11]
Go 6983	DMKVTZN	Discovery agent	N.A.	Investigative	[13]
K00248	DMWZJG6	Discovery agent	N.A.	Investigative	[12]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[14]
O-Phosphoethanolamine	DM3O9YW	N. A.	N. A.	Investigative	[15]
PROSTRATIN	DM1HMJ5	Human immunodeficiency virus infection	1C62	Investigative	[16]
PUNICAFOLIN	DM7CWQY	Discovery agent	N.A.	Investigative	[17]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[18]
Ro-32-0557	DMPVKEA	Discovery agent	N.A.	Investigative	[9]
TANNIN	DMTFHRI	Discovery agent	N.A.	Investigative	[17]
[2,2':5',2'']Terthiophen-4-yl-methanol	DMRQC1F	Discovery agent	N.A.	Investigative	[19]
[2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde	DMWDNLI	Discovery agent	N.A.	Investigative	[19]
[2,2':5',2'']Terthiophene-4-carbaldehyde	DM2S5EJ	Discovery agent	N.A.	Investigative	[19]

References

• [1] The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008 Jul;49(7):1374-83.
• [2] Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-9.
• [3] Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003 Feb;52(2):512-8.
• [4] Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
• [5] ClinicalTrials.gov (NCT03492125) A Study Of The Selective PKC-beta Inhibitor MS- 553. U.S. National Institutes of Health.
• [6] Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol. 2002 May;133(5):693-8.
• [7] Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
• [8] Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
• [9] Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
• [10] (-)-Cercosporamide derivatives as novel antihyperglycemic agents. Bioorg Med Chem Lett. 2009 Feb 1;19(3):724-6.
• [11] Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83.
• [12] Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4.
• [13] Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80.
• [14] (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
• [15] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [16] A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
• [17] Tannins as selective inhibitors of protein kinase C, Bioorg. Med. Chem. Lett. 2(3):239-244 (1992).
• [18] Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
• [19] Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82.